AU2002229928A1 - Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases - Google Patents

Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Info

Publication number
AU2002229928A1
AU2002229928A1 AU2002229928A AU2002229928A AU2002229928A1 AU 2002229928 A1 AU2002229928 A1 AU 2002229928A1 AU 2002229928 A AU2002229928 A AU 2002229928A AU 2002229928 A AU2002229928 A AU 2002229928A AU 2002229928 A1 AU2002229928 A1 AU 2002229928A1
Authority
AU
Australia
Prior art keywords
treatment
neurological diseases
myelin
antagonists
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002229928A
Other languages
English (en)
Inventor
Elaine Alison Irving
Mary Vinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2002229928A1 publication Critical patent/AU2002229928A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AU2002229928A 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases Abandoned AU2002229928A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0103174.9 2001-02-08
GBGB0103174.9A GB0103174D0 (en) 2001-02-08 2001-02-08 Novel method of treatment
PCT/GB2002/000551 WO2002062383A2 (en) 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Publications (1)

Publication Number Publication Date
AU2002229928A1 true AU2002229928A1 (en) 2002-08-19

Family

ID=9908386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002229928A Abandoned AU2002229928A1 (en) 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Country Status (11)

Country Link
US (2) US20040170627A1 (https=)
EP (2) EP1357941B1 (https=)
JP (2) JP5005156B2 (https=)
AT (1) ATE314861T1 (https=)
AU (1) AU2002229928A1 (https=)
CY (1) CY1105549T1 (https=)
DE (1) DE60208534T2 (https=)
DK (1) DK1357941T3 (https=)
ES (1) ES2254655T3 (https=)
GB (1) GB0103174D0 (https=)
WO (1) WO2002062383A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP3211084B1 (en) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA06000176A (es) * 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
WO1997001352A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
EP1047449B1 (en) * 1997-10-28 2003-09-10 The University Of British Columbia Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
IL136114A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
JP2004523538A (ja) 2004-08-05
WO2002062383A2 (en) 2002-08-15
CY1105549T1 (el) 2010-07-28
EP1357941A2 (en) 2003-11-05
WO2002062383A3 (en) 2003-04-10
EP1645285A2 (en) 2006-04-12
DK1357941T3 (da) 2006-05-01
DE60208534D1 (de) 2006-03-30
JP2008291031A (ja) 2008-12-04
EP1645285A3 (en) 2010-04-14
ES2254655T3 (es) 2006-06-16
GB0103174D0 (en) 2001-03-28
DE60208534T2 (de) 2006-11-30
US20080014195A1 (en) 2008-01-17
EP1357941B1 (en) 2006-01-04
US20040170627A1 (en) 2004-09-02
ATE314861T1 (de) 2006-02-15
JP5005156B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DE60236646D1 (de) Anti-VEGF-2 Antikörper
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
MXPA03005048A (es) Anticuerpos humanizados que reconocen el peptido amiloideo beta.
SI1624892T1 (sl) Terapevtska uporaba protiteles anti-CS1
IL207875A0 (en) Alzheimer's disease treatment method
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
AU2002229928A1 (en) Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2002059346A3 (en) Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
IL147188A (en) Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases
WO2004083363A3 (en) Therapeutical use of anti-myelin associated glycoprotein (mag) antibodies
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
WO2005042028A3 (en) Il-13 conjugated to an immunogen and uses thereof
AU2001230589A1 (en) Therapeutic and/or preventive agents for optic nerve diseases and retinal diseases
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
AU2002347287A1 (en) Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase